Treg Directed Therapy for Autoimmune Disorders Summit 2018

Memo

This is your first and only opportunity to listen to the most advanced clinical case studies from Nektar Therapeutics and Amgen which explore the use of IL-2 to enhance the expansion and activation of the Treg cells. Delve deeper with expert insights from Roche and ILTOO Pharma to understand how IL-2 at low doses could selectively stimulate Treg cells.



Identify yourself as a leader in this community and join the discussion exploring the challenges in translating a proof of concept in autoimmune therapies from animal models to clinic. This meeting will provide the platform for conversations to be had to accelerate the clinical translation of Treg directed therapies.



URLs:

Brochure: https://go.evvnt.com/197029-1?pid=5569

Inquiries: https://go.evvnt.com/197029-2?pid=5569

Website: https://go.evvnt.com/197029-3?pid=5569



Prices

Conference Only (Earlybird ends Feb 23): USD 1999

Conference Only (Earlybird ends Mar 23): USD 2199

Conference Only (Earlybird ends Apr 20): USD 2399

Conference Only: USD 2799

Conference Academic Only (Earlybird ends Feb 23): USD 1399

Conference Academic Only (Earlybird ends Mar 23): USD 1599

Conference Academic Only (Earlybird ends Apr 20): USD 1799

Conference Academic Only: USD 1999

Workshop Only: USD 499



Speakers: Chris Haqq, Kevin Gorski, Nadia Tchao, David Wraith, Andrew Scharenberg, Simrit Parmar, Robert Plenge, Stephen Miller, Todd Brusko, Jérémie Mariau, Laurence Turka, Jason Fontenot, Leonard Dragone, Jonathan Zalevsky, Aaron Winkler, David Klatzmann, Jonathan Esensten, Leslie Kean, Annalisa D’Andrea, Rosa Bacchetta, Qizhi Tang, Dennis Kasper, Stephane Boissel, Pierre Heimendinger, Rose Szabady, David Hafler



Venue details

Westin Boston Waterfront

425 Summer Street, Boston, MA 02210, United States



Tuesday May 22, 2018 at 8:00 am (ends Thursday May 24, 2018 at 4:00 pm)